Rutaecarpine

Other Names

3,13,21-Triazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-1(21),2(10),4(9),5,7,15(20),16,18-octaen-14-one3,13,21-Triazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-1(21),2(10),4,6,8,15,17,19-octaen-14-one5,7,8,13-Tetrahydroindolo[2',3':3,4]pyrido[2,1-b]quinazoline-5-one7,8-Dihydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(13H)-one8,13-Dihydro-7H-indolo[2'',3'':3,4]pyrido[2,1-b]quinazolin-5-one8,13-Dihydroindolo[2',3':3,4]pyrido[2,1-b]chinazolin-5(7H)-on8,13-Dihydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7H)-oneCHEBI:8922Indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7H)-one, 8,13-dihydro-NSC 258317RhetineRUTRutacarpineRutaecarpinRutecarpineRUTECARPINE [MI]

Synopsis

Rutaecarpine: A Comprehensive Reference Article

1. Identity and Chemical Characterization

Nomenclature

The alkaloid rutaecarpine (8,13-dihydroindolo-[2′,3′:3,4]pyrido[2,1-b]quinazolin-5(7H)-one) was first isolated in 1915 by Asahina and Kashiwaki from an acetone extract of Evodia rutaecarpa. It is also frequently rendered in literature as rutecarpine. Rutaecarpine (RUT) is a natural pentacyclic indolopyridoquinazolinone alkaloid first isolated from one of the most famous traditional Chinese herbs, Evodia rutaecarpa. The compound carries CAS registry number 84-26-4, has a molecular weight of 287.3 Da and the molecular formula C₁₈H₁₃N₃O.

Botanical Source and Taxonomy

Tetradium ruticarpum is a tree that comes from China and Korea. It was previously classified in the genus Euodia as Euodia ruticarpa. The fruit is usually used, denoted sometimes as fructus. It has a strong bitter taste, and is used in traditional Chinese medicine (TCM) and is a recognized herb in Kampo. Both the former genus name and the species name are often misspelled, and the plant usually appears in sources dealing with traditional Chinese medicine as "Evodia(e) rutaecarpa".

Rutaecarpine is a major alkaloid compound isolated from Wu Zhu Yu. Indole alkaloids, particularly evodiamine (EVO), rutaecarpine (RUT), and dehydroevodiamine (DHE), have received rising attention as the major bioactivity compounds in Evodia rutaecarpa. The plant belongs to the family Rutaceae, and it has been clinically applied and officially recorded in the Chinese Pharmacopoeia 2015 Edition.

Chemical Class and Physical Properties

Rutaecarpine is an indolopyridoquinazolinone alkaloid isolated from Evodia rutaecarpa and related herbs. It is classified as a non-basic alkaloid. Rutaecarpine metabolism is complex and proceeds along several routes, primarily involving the addition of a single hydroxyl group by CYP3A4. Six monohydroxylated and four dihydroxylated metabolites have been identified.

Extraction, Synthesis, and Common Forms

At present, rutaecarpine is mainly obtained by chemical synthesis or phytoextraction. Many researchers have also synthesized a series of derivatives and analogues of rutaecarpine by chemical modification, aiming to improve its pharmacological activity and reduce its toxic effects. As a dietary supplement, rutaecarpine is commercially available primarily as standardized capsules or tablets of dried fruit extract or isolated alkaloid. Studies have shown that microemulsions significantly enhance the transdermal delivery of evodiamine and rutaecarpine, offering an effective method for administering these alkaloids.

2. Traditional and Historical Use

Traditional Chinese Medicine (TCM)

Rutaceous plants, especially Evodia rutaecarpa (whose dried fruit is named "Wu-Chu-Yu" in China), have been widely used for the treatment of gastrointestinal disorders, headache, amenorrhea, and postpartum hemorrhage in traditional oriental medicine for hundreds of years. Like other Chinese herbal medicines, EF has been reported to be relatively safe in the book of "Shen Nong's Herbal Classic," the most ancient book recording the use of traditional Chinese medicine.

Rutaecarpine is a natural pentacyclic indolopyridoquinazolinone alkaloid first isolated from one of the most famous traditional Chinese herbs, Evodia rutaecarpa, which is used for treating a variety of ailments, including headaches, gastrointestinal disorders, postpartum hemorrhage, amenorrhea, difficult menstruation, and other diseases. The plant has a long history of usage in TCM as a warming technique to reduce pain, gastrointestinal distress, and as an anticancer agent.

Kampo (Japanese Traditional Medicine)

Tetradium ruticarpum is called 呉茱萸 (Goshuyu) in Japanese, used in Goshuyu-tou and Unkentou (温経湯). These are Kampo (漢方) preparations of mixed herbs, the former named after this plant. In TCM, the T. ruticarpum formulation "Oren-geduku-to" has been used for antioxidant, anti-inflammatory, and neuroprotective activities.

Preparations in Traditional Use

Evodia rutaecarpa, the near-ripe fruit of Euodia rutaecarpa (Juss.) Benth, Euodia rutaecarpa (Juss.) Benth. var. officinalis (Dode) Huang, or Euodia rutaecarpa (Juss.) Benth. var. bodinieri (Dode) Huang, is a famous herbal medicine with several biological activities and therapeutic values, which has been applied for abdominalgia, abdominal distension, vomiting, and diarrhea as a complementary and alternative therapy in clinic. In TCM formulas, Wu Zhu Yu (Fructus Evodiae) refers specifically to the dry, nearly ripe fruit of the plant.

3. Key Constituents and Active Compounds of Evodia rutaecarpa

Major bioactive ingredients isolated from the Evodia fruit are alkaloid compounds, including rutaecarpine, evodiamine, and dehydroevodiamine (DHED). An increasing body of evidence has revealed that these alkaloid compounds have extensive pharmacological actions, ranging from anti-inflammatory, anti-obesity, anti-oxidant, anti-cancer, vasodilatory, anti-fibrotic, anti-platelet activation effects, to lipid-lowering effects.

A considerable amount of bioactive ingredients have been isolated and identified from the roots of T. ruticarpum, including alkaloids, saponins, phenols, volatile oils and other compounds. Rutaecarpine is consistently identified as one of the most studied and most representative alkaloids of the plant.

4. Mechanisms of Action

TRPV1 Receptor Activation and CGRP Release

The activation of transient receptor potential vanilloid (TRPV1, also named capsaicin receptor), a receptor primarily expressed in sensory nerves innervating the heart and blood vessels, is central to rutaecarpine's cardiovascular effects. The activation of TRPV1 consequently induces the release of calcitonin gene-related peptide (CGRP), the principal transmitter in capsaicin-sensitive sensory nerves. Rutaecarpine promotes the release of CGRP in a concentration-dependent manner, and exposure to capsazepine, a TRPV1 receptor antagonist, suppresses CGRP expression. TRPV1 receptor blockers have been demonstrated to counteract the vasodilation effects of rutaecarpine, suggesting that rutaecarpine protects the cardiovascular system by releasing CGRP through the activation of the TRPV1 receptor.

COX-2 Inhibition

Rutaecarpine inhibited COX-2 and COX-1 dependent phases of PGD2 generation in bone marrow-derived mast cells (BMMC) in a concentration-dependent manner, with an IC50 of 0.28 μM and 8.7 μM, respectively. It inhibited COX-2-dependent conversion of exogenous arachidonic acid to PGE2 in a dose-dependent manner in COX-2-transfected HEK293 cells. Rutaecarpine did not inhibit PLA2 or COX-1 activity nor COX-2 protein and mRNA expression up to a concentration of 30 μM in BMMC, indicating that rutaecarpine directly inhibited COX-2 enzymatic activity.

NF-κB and Inflammatory Signaling

Western blot and spectrophotometric results revealed that rutaecarpine inhibited the production of nitric oxide (NO) and the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and interleukin (IL)-1β in lipoteichoic acid (LTA)-induced macrophage cells. Notably, RUT exerted definite anti-inflammatory, anti-oxidation, and anti-apoptosis effects in several experimental pathologies through the signaling of NF-κB, Nrf2/HO-1, and Bcl-2/Bax pathways.

AMPK/PGC-1α Pathway and Thermogenesis

Rutaecarpine promoted brown adipocyte mitochondrial biogenesis and thermogenesis in vitro. Chronic rutaecarpine treatment reduced body weight gain and mitigated insulin sensitivity through brown and beige adipocyte thermogenesis. Mechanistic study showed that rutaecarpine activated the energy metabolic pathway AMP-activated protein kinase (AMPK)/PGC-1α axis, and deficiency of AMPK abolished the beneficial metabolic phenotype of rutaecarpine treatment in vitro and in vivo.

Endothelial Nitric Oxide Synthesis

In human endothelial cells, rutaecarpine demonstrated effects on nitric oxide (NO) synthesis via endothelial nitric oxide synthase (eNOS) phosphorylation. RUT treatment promoted NO generation by increasing eNOS phosphorylation. Additionally, RUT induced an increase in intracellular Ca²⁺ concentration and phosphorylation of Ca²⁺/calmodulin-dependent protein kinase kinase β (CaMKKβ), AMP-activated protein kinase (AMPK), and Ca²⁺/calmodulin-dependent kinase II (CaMKII). Inhibition of TRPV1 attenuated RUT-induced intracellular Ca²⁺ concentration and phosphorylation of CaMKII, CaMKKβ, AMPK, and eNOS. RUT also attenuated the expression of ICAM-1 and VCAM-1 induced by TNF-α and inhibited the inflammation-related NF-κB signaling pathway.

Lipid Metabolism and Cholesterol Efflux

In RAW264.7 macrophages, HepG2 cells, and primary murine macrophages from female mice, rutaecarpine upregulated ABCA1 and SR-B1 expression. In a liver cell line, rutaecarpine directly bound to the LXRα-LBD and LXRβ-LBD. In apoE⁻/⁻ mice under a high-fat diet, rutaecarpine reduced atherosclerotic lesions and plasma total cholesterol, LDL cholesterol, and triglyceride levels.

CYP Enzyme Induction and Inhibition

A cocktail assay showed that CYP1A2, CYP2C9, CYP2C19, CYP2E1, and CYP3A4 can be inhibited by rutaecarpine in human liver microsomes. The IC50 values of CYP1A2 with and without NADPH were 2.2 and 7.4 μM, respectively, presenting a 3.3-fold shift. Microsome studies suggest that rutaecarpine may be at least a weak inhibitor of CYP1A2, CYP2C9, CYP2C19, CYP2E1, and CYP3A4 enzymes. At the same time, it is believed to be a strong inducer of CYP1A2 and CYP1A1.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular System

As one of the most representative indolopyridoquinazoline alkaloids of Evodia rutaecarpa, rutaecarpine has broad pharmacological actions in treating various cardiovascular, cerebrovascular, and metabolic diseases. The cardiovascular actions of rutaecarpine have aroused intense research interest due to its purported inotropic and chronotropic, vasodilatory, anti-platelet activation, anti-oxidant, anti-inflammatory, and lipid-lowering effects.

Rutaecarpine (3 μM) has been reported to have transient positive inotropic and chronotropic effects on the guinea pig isolated right atria. Later studies reveal that CGRP also mediates the cardioprotective effects of rutaecarpine in some animal ischemia heart disease models.

Evidence strength: Although rutaecarpine has displayed a wide range of cardiovascular actions, and the molecular targets of rutaecarpine are being elucidated, the therapeutic utility of rutaecarpine in clinical management of cardiovascular diseases remains unknown. Since most clinical trials of rutaecarpine are performed in China with limited sample size, large-scale, randomized, multi-center clinical trials are warranted to assess whether rutaecarpine and its derivatives can be applied to treat patients with cardiovascular diseases safely and effectively. The cardiovascular evidence base is therefore largely preclinical (in vitro and animal models).

5.2 Anti-Inflammatory Activity

Rutaecarpine showed in vivo anti-inflammatory activity on rat lambda-carrageenan induced paw edema by intraperitoneal administration. Anti-inflammatory activity of Evodia rutaecarpa could be attributed at least in part to inhibition of COX-2.

The release of inflammatory cytokines, such as prostacyclin (PG) E2 or PGD2, plays an important role in the inflammatory reaction. Rutaecarpine (1–10 μM) reduces the production of PGE2 treated with lipopolysaccharide (LPS) or ultraviolet B (UVB) in a dose-dependent manner.

Evidence strength: Anti-inflammatory evidence for rutaecarpine is predominantly derived from in vitro cell studies and animal experiments. No large-scale human clinical trials specifically demonstrating anti-inflammatory effects of isolated rutaecarpine have been identified in the peer-reviewed literature.

5.3 Obesity, Thermogenesis, and Metabolic Effects

One study found that rutaecarpine promoted brown adipocytes' mitochondrial biogenesis and thermogenesis in vitro. Chronic rutaecarpine treatment reduced body weight gain and mitigated insulin sensitivity through brown and beige adipocyte thermogenesis.

Rutaecarpine (20 or 100 mg/kg, i.p.) was recently reported to ameliorate body weight gain, which is related to the inhibition of orexigenic neuropeptide Y and agouti-related protein. These two neuropeptides play major roles in feeding and are closely related to obesity and diabetic metabolic syndrome. The above results suggest that rutaecarpine has potential effects on diabetic metabolic syndrome.

Studies showed that rutaecarpine extracted from Evodia rutaecarpa promotes glucose consumption and anti-inflammatory cytokine expression in insulin-resistant primary skeletal muscle cells. Investigators examined whether rutaecarpine ameliorated obesity profiles, lipid abnormality, glucose metabolism, and insulin resistance in a rat model of hyperlipidemia and hyperglycemia. Rats were fed a high-fat diet for 8 weeks, followed by injection of streptozotocin (30 mg/kg, i.p.) to induce hyperlipidemia and hyperglycemia. One week after streptozotocin injection, the fat-fed, streptozotocin-treated rats were orally treated with rutaecarpine (25 mg·kg⁻¹·d⁻¹) or a positive control drug metformin (250 mg·kg⁻¹·d⁻¹) for 7 weeks.

Evidence strength: Evidence for anti-obesity and thermogenic effects comes entirely from animal and cell studies. No human clinical trials have been completed and reported for these specific outcomes with isolated rutaecarpine.

5.4 Gastrointestinal Protection

The Evodia fruit has been applied for abdominalgia, abdominal distension, vomiting, and diarrhea as a complementary and alternative therapy in clinical settings.

Rutaecarpine, isolated from the TCM of Evodia rutaecarpa, was reported to suppress inflammatory bowel disease (IBD). By using nuclear factor-erythroid 2–related factor 2 (NRF2) knockout mice, cell-based studies, surface plasmon resonance (SPR), western blotting analysis, and molecular docking studies, the mechanism by which RUT affects DSS-induced colitis was explored. In DSS-treated wild-type mice but not in Nrf2-null mice, RUT significantly improved colitis as revealed by rescued body weight loss, improved histology and inflammation, and induced expression of NRF2 target genes in colon and ileum.

Rutaecarpine, a major quinazolino carboline alkaloid compound from the dry unripe fruit of Tetradium ruticarpum, has various pharmacological effects. The aim of one study was to investigate the potential gastroprotective effect of rutaecarpine on ethanol-induced acute gastric mucosal injury in mice and associated molecular mechanisms, such as activating Nrf2 and Bcl-2 via PI3K/AKT signaling pathway and inhibiting NF-κB.

Evidence strength: Gastrointestinal evidence is primarily from animal models. Traditional use in humans is long-established, but controlled human clinical trials on isolated rutaecarpine for GI outcomes are lacking.

5.5 Anticancer Activity

In colorectal cancer (CRC) research, RUT was found to inhibit the proliferation, migration, and invasion of CRC cells in vitro. Further, RUT induced the apoptosis of CRC cells. Mechanistically, RUT decreased the phosphorylation levels of NF-κB and STAT3. Treatment with RUT upregulated the expression of cleaved-Caspase3 and downregulated the expression of Bcl-2 in CRC. In addition, findings suggested that RUT inhibited the growth and lung metastasis of CRC cells in vivo.

One study found that rutaecarpine also has great potential in antagonizing drug resistance. The study proved for the first time that rutaecarpine can downregulate the protein level of ABCB1, and its combined use with anticancer drugs can induce the apoptosis of drug-resistant cells.

Evidence strength: Anticancer evidence is exclusively in vitro and animal-based. No human clinical trials on rutaecarpine as a standalone anticancer agent have been reported. The relevance of these findings for human cancer treatment is currently unknown and requires substantial further investigation.

5.6 Hepatoprotective Effects

Evodiamine (EVO) and rutaecarpine (RUT) are believed to be the most bioactive alkaloids in T. ruticarpum, having anti-inflammation, anti-fibrosis, anti-lipotoxicity, and anti-cancer activities, and thus having potential to improve liver disorders.

One study investigated the effect of rutaecarpine on acetaminophen-induced hepatotoxicity in mice. Rutaecarpine was administered orally daily for seven consecutive days, followed by intraperitoneal injection of acetaminophen in mice on day seven to induce hepatotoxicity. Rutaecarpine pretreatment significantly decreased acetaminophen-induced serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) activities and hepatic malondialdehyde content and prevented acetaminophen-induced hepatic glutathione depletion.

Evidence strength: Hepatoprotective evidence is from animal studies only. Importantly, conflicting data exist regarding rutaecarpine's overall hepatic impact (see Safety section below).

5.7 Caffeine Metabolism and Sleep

Rutaecarpine is reported as a potent inducer of CYP1A2 enzyme in rats. There are natural herbal supplements containing rutaecarpine that are designed to enhance the CYP1A2-dependent removal of caffeine from blood so that people can have coffee later in the day without causing sleep interference.

Results showed that orally administered rutaecarpine at 100 mg/kg dose as early as 3 hours before oral caffeine administration significantly decreased the oral systemic exposure and mean residence time of caffeine and its metabolites due to decreased caffeine bioavailability (by up to 75%) and increased clearance.

Evidence strength: Evidence for caffeine elimination is from rat pharmacokinetic studies. Human data are absent. The dose studied in rats (100 mg/kg) does not translate directly to human supplement doses, and no human trials have assessed rutaecarpine's impact on caffeine metabolism or sleep quality.

5.8 Neurological and Cognitive Effects

RUT has shown versatile beneficial effects in several experimental models, such as colitis, atherosclerosis, cerebral ischemia-reperfusion, hypertension, acute kidney injury, type 2 diabetes, and Alzheimer's disease. Traditional claims of this plant have been validated with published reports on AChE inhibitory activities, as in vitro and in vivo results showed that E. rutaecarpa reversed the scopolamine-induced memory impairment in rats.

Recent studies have demonstrated that rutaecarpine possesses extensive biological and pharmacological properties, such as diuresis, perspiration, uterotonic action, improvement of cerebral functions, and antinociception.

Evidence strength: Neuroprotective and cognitive effects are supported only by in vitro and animal data.

6. Body Systems and Health Areas Associated with Rutaecarpine

Cardiovascular system: Rutaecarpine has been shown to have cardiovascular biological effects such as inotropic and chronotropic, vasorelaxant, anti-platelet aggregation, and anti-inflammatory effects.
Gastrointestinal system: Rutaecarpine has long been explored for the potential treatment of cardiovascular diseases, gastrointestinal disorders, headaches, Alzheimer's disease, and acute pancreatitis.
Metabolic/Endocrine system: Rutaecarpine has shown intriguing biological properties such as anti-obesity and thermoregulatory activity, as well as effects on the cardiovascular and endocrine systems.
Immune and inflammatory system: Rutaecarpine modulates inflammation through multiple pathways including COX-2 inhibition and NF-κB suppression.
Oncological: Findings indicate that RUT can inhibit the proliferation and migration of CRC cells, and induce the apoptosis of CRC cells by inactivating NF-κB/STAT3 signaling.
Neurological: Rutaecarpine has been studied in experimental models of Alzheimer's disease and cerebral ischemia-reperfusion.
Hepatic: Many studies have demonstrated that rutaecarpine has great potential for the treatment of colitis, liver disease, acute pancreatitis, diabetes, and Alzheimer's disease.

7. Dosage Forms and Reported Dosages

Rutaecarpine is available as an isolated alkaloid (typical purity ≥98%) used in research settings, and as a constituent of standardized Evodia rutaecarpa fruit extracts in dietary supplement capsules.

The following dosages are those reported in published preclinical (animal) studies — no established clinical human dosage guidelines exist:

In a rat model of hyperlipidemia and hyperglycemia, fat-fed, streptozotocin-treated rats were orally treated with rutaecarpine at 25 mg·kg⁻¹·d⁻¹ for 7 weeks.
Rutaecarpine at 20 or 100 mg/kg (i.p.) was reported to ameliorate body weight gain in rodent models.
Rutaecarpine at 10 and 40 mg/kg (intragastric) reversed cardiac remodeling induced by isoprenaline in animal models.
In caffeine pharmacokinetic studies in rats, orally administered rutaecarpine at 100 mg/kg dose was used to study its interaction with caffeine metabolism.
In cell-based (BMMC) anti-inflammatory studies, rutaecarpine inhibited COX-2-dependent PGD2 generation with an IC50 of 0.28 μM.
In isolated guinea pig right atria studies, rutaecarpine at 3 μM was reported to have transient positive inotropic and chronotropic effects.

In the commercial supplement context, the recommendation reported for one supplement brand was to take two capsules equivalent to 100 mg rutaecarpine, as needed, to reduce caffeine level. This dosage has not been validated in human clinical trials.

8. Safety Considerations and Drug Interactions

CYP Enzyme Interactions

Rutaecarpine caused the most dramatic decrease in residual CYP3A4 activity and was further identified as a mechanism-based inhibitor of CYP3A4. Rutaecarpine also showed potent inhibition of CYP1A1 and CYP1A2 (IC50 of 0.90 and 0.06 μM). These inhibitory effects at the same time as its inductive effects on CYP1A2 create a complex and bidirectional interaction profile with drug-metabolizing enzymes.

Rutaecarpine can inhibit the activities of CYPs and exhibits potential mechanism-based inhibition on CYP1A2. Reactive metabolites may cause herb–drug interactions, providing important information for predicting drug-induced hepatotoxicity.

Caffeine and Drug Metabolism Interactions

Rutaecarpine has been shown to increase the metabolism and elimination of caffeine, theophylline, acetaminophen, and Rhizoma coptidis alkaloids. This is particularly relevant in the context of co-administration with medications that are CYP1A2 substrates, as rutaecarpine may substantially alter their circulating levels.

Although plasma levels of rutaecarpine were undetectable (less than 10 ng/mL) in rats, rutaecarpine still induced hepatic CYP1A2 activity. Results showed that 3 hours after one rutaecarpine oral dose, CYP1A2 activity in rat liver tissue was increased 3-fold.

Hepatotoxicity: Conflicting Data

Rutaecarpine is one of the main active components used in a variety of clinical applications, including the treatment of hypertension and arrhythmia. However, its hepatotoxicity has also been reported in recent years.

Reactive metabolites (RMs) play a vital role in drug-induced liver injury. Rutaecarpine has a secondary amine structure that may be activated to reactive metabolites. Cell counting kit-8 cytotoxicity assay indicated that rutaecarpine can decrease primary rat hepatocyte viability, increase lactate dehydrogenase and reactive oxygen species, reduce JC-1, and cause cell stress and membrane damage.

The impact of rutaecarpine on hepatotoxicity remains uncertain, while some evidence indicates that rutaecarpine may protect against acetaminophen-induced liver damage by enhancing Nrf2-mediated antioxidant enzyme activity. However, other reports suggest that rutaecarpine could worsen drug-induced liver injury, such as acetaminophen-induced hepatotoxicity, by altering acetaminophen pharmacokinetics and inhibiting CYP activity.

One study focused on how rutaecarpine, as a component of TCM, exacerbates APAP-induced acute liver damage by inducing the drug-metabolizing enzyme CYP1A2. The findings underscore the importance of understanding these drug interactions and their metabolic mechanisms to ensure the safe and effective use of combined TCM and synthetic drug therapies.

Acetaminophen (Paracetamol) Interaction

The interaction between rutaecarpine and acetaminophen is a noted area of concern. On one hand, rutaecarpine pretreatment at certain doses has shown protective effects in acetaminophen-hepatotoxicity models; on the other hand, by inducing CYP1A2, rutaecarpine may shift acetaminophen metabolism toward more toxic metabolite pathways. These findings highlight the need for caution when rutaecarpine-containing products are combined with acetaminophen.

Physicochemical Limitations

Accumulating pharmacological studies showed that rutaecarpine possesses a wide range of pharmacological effects through different mechanisms. However, its poor physicochemical properties and moderate biological activities have hampered its clinical application. The compound has limited aqueous solubility, which affects oral bioavailability and may account in part for the large discrepancies between in vitro and in vivo potency.

Overall Evidence Gaps

Interest in the molecule has been growing, presumably due to its characteristic structure and intriguing biological properties (733 references were found in the SciFinder database provided by the American Chemical Society). In addition, 55 patents have been issued regarding its isolation, biological activity, synthesis, metabolism, and toxicology. Despite this large body of preclinical research, robust human clinical trial evidence for rutaecarpine as an isolated compound is absent across all therapeutic areas reviewed. Virtually all studied outcomes derive from cell cultures or animal experiments, making any direct translation to human health effects speculative until appropriately designed trials are conducted.

References

Health Conditions

Health conditions that Rutaecarpine may help support.

No conditions available.

Body Systems

Body systems that Rutaecarpine may help support.

No body systems available.